1. Home
  2. IRT vs CRNX Comparison

IRT vs CRNX Comparison

Compare IRT & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Independence Realty Trust Inc.

IRT

Independence Realty Trust Inc.

HOLD

Current Price

$16.42

Market Cap

4.0B

Sector

Real Estate

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$83.85

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IRT
CRNX
Founded
2009
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
3.9B
IPO Year
2009
2018

Fundamental Metrics

Financial Performance
Metric
IRT
CRNX
Price
$16.42
$83.85
Analyst Decision
Buy
Strong Buy
Analyst Count
10
8
Target Price
$20.45
$76.75
AVG Volume (30 Days)
2.4M
7.0M
Earning Date
04-29-2026
05-07-2026
Dividend Yield
4.17%
N/A
EPS Growth
41.18
N/A
EPS
N/A
N/A
Revenue
$657,696,000.00
$1,039,000.00
Revenue This Year
$3.21
$720.10
Revenue Next Year
$3.54
$184.67
P/E Ratio
$68.10
N/A
Revenue Growth
2.76
N/A
52 Week Low
$14.60
$25.83
52 Week High
$18.19
$84.00

Technical Indicators

Market Signals
Indicator
IRT
CRNX
Relative Strength Index (RSI) 46.19 92.12
Support Level $15.81 $43.40
Resistance Level $16.79 N/A
Average True Range (ATR) 0.38 0.19
MACD -0.05 -0.48
Stochastic Oscillator 18.25 75.00

Price Performance

Historical Comparison
IRT
CRNX

About IRT Independence Realty Trust Inc.

Independence Realty Trust Inc is a real estate investment trust (REIT) that acquires, owns, operates, improves and manages multifamily apartment communities across non-gateway U.S. markets. It owns and operates multifamily apartment properties, across non-gateway U.S markets, including Atlanta, Columbus, Dallas, Denver, Houston, Indianapolis, Nashville, Oklahoma City, Raleigh-Durham, and Tampa. The company is focused on gaining scale within key amenity-rich submarkets that offer school districts, retail, and various employment centers.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: